Development of drug resistance to standard
chemotherapy is a common phenomenon that leads to poor prognosis in patients. Thus, novel agents that can attenuate chemoresistance are urgently needed. Therefore, we analyzed whether
isorhamnetin (IH), a 3'-O-methylated metabolite of
quercetin, can enhance the potential efficacy of
capecitabine in
gastric cancer. The potential effect of IH on viability was analyzed by MTT assay, apoptosis by flow cytometric analysis, and NF-κB activation by
DNA binding as well as Western blot assays. The in vivo effect of IH was also examined on the growth of subcutaneously implanted
tumors in nude mice. IH inhibited the viability, potentiated the apoptotic effects of
capecitabine, abrogated NF-κB activation, and suppressed the expression of various NF-κB regulated gene products in
tumor cells. In a
gastric cancer xenograft model, administration of IH alone (1 mg/kg
body weight, i.p.) significantly suppressed the
tumor growth alone as well as in combination with
capecitabine. IH further reduced NF-κB activation and the expression of various proliferative and oncogenic
biomarkers in
tumor tissues. Overall, our results demonstrate that IH can significantly enhance the anti-
tumor effects of
capecitabine through the negative regulation of NF-κB regulated oncogenic genes.